Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Ikena Oncology
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06270082CT.gov Study of IK-595 in RAS- or RAF-altered Advanced Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thyroid Gland Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ik-595 (this asset) | Ikena Oncology | P1 | CC · 43 |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Olaparib | University Medical Center Groningen | P4 | BB |
| Pazopanib | University Medical Center Groningen | P4 | B |
| Cetuximab | Institut de Recherches Internationales Servier | P1/2 | CCC |
| Tislelizumab | SOLTI Breast Cancer Research Group | P2 | CCC |
| Ulixertinib | National Cancer Institute (NCI) | P2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P2 | CCC |
+31 more in the Thyroid Gland Carcinoma cohort
Other indications for ik-595
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Malignant Glioma | — | P1 | CC · 43 |
| Melanoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ik-595 in Thyroid Gland Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ik-595-thyroid-gland-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →